Trial reportHaematologica2015
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Trial report in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Trial
- Establishment of a histiocytic sarcoma cell line and anti-tumor effect of bortezomib in the African pygmy hedgehog (Atelerix albiventris).The Journal of veterinary medical science · 2024Article
- Daratumumab in the treatment of C3 glomerulopathy with monoclonal gammopathy: a case report and literature review.Frontiers in medicine · 2023Article
- An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.Therapeutic advances in hematology · 2022Review
- Supportive care in multiple myeloma: Current practices and advances.Cancer treatment and research communications · 2021Article
- Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.European journal of haematology · 2020Article
- Article
- Nanotherapeutics for multiple myeloma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2018Review
- Proteasome-associated deubiquitinases and cancer.Cancer metastasis reviews · 2017Review
- Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Mayo Clinic proceedings · 2017Review
- Update on the optimal use of bortezomib in the treatment of multiple myeloma.Cancer management and research · 2017Review
- New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.Journal of blood medicine · 2017Review
- A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.British journal of haematology · 2016Article
- Spotlight on ixazomib: potential in the treatment of multiple myeloma.Drug design, development and therapy · 2016Review
- The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.Patient preference and adherence · 2015Review
- Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden.Acta haematologicaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.